Cough: Clinical Trials

48 trials for Cough, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 completed. 48 Phase 2, 7 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 248Completed 48
Phase 17Completed 7
Phase 31Completed 1

Follow Cough: new trials by email Literature Review of Cough trials Research Report on Cough

Trials (filtered) newest first · largest first

All 48 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy Reconyl for Cough With/Without Sore Throat
Reconyl, Placebo tablet of Reconyl - Cough
Phase 2CompletedDexa Medica Group602024-07-232025-02-07
Cough Reduction in IPF With Nalbuphine ER
NAL ER, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2CompletedTrevi Therapeutics1652024-02-062026-06-26
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
NAL ER, Placebo - Refractory Chronic Cough
Phase 2CompletedTrevi Therapeutics662023-11-302026-03-30
QR052107B Tablets in Patients With Subacute Cough of Phase Ⅱ Study
QR052107B 100 mg, QR052107B 400 mg, Placebo - Cough
Phase 2CompletedWuhan Createrna Science and Technology Co., Ltd2702023-06-212025-04-10
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
HRS-2261 oral tablet, Matching placebo to HRS-2261 - Refractory Chronic Cough
Phase 2CompletedGuangdong Hengrui Pharmaceutical Co., Ltd972023-03-092026-01-21
Bolus vs. Continuous IV Lidocaine Against Post-Extubation Cough in Post-Thyroidectomy Patients
Lidocaine IV - Cough
Phase 2CompletedUniversitas Padjadjaran402023-02-022023-09-22
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
Orvepitant Maleate, Placebo - Cough, Idiopathic Pulmonary Fibrosis
Phase 2CompletedNerre Therapeutics Ltd.802022-08-012025-11-10
A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough
ADX-629, Placebo - Chronic Cough
Phase 2CompletedAldeyra Therapeutics, Inc.512022-04-072025-02-28
A Study of Efficacy and Safety of AX-8 in Chronic Cough
AX-8, Part 1 of the study, Placebo, Part 1 of the study, AX-8, Part 2 of the study - Chronic Cough
Phase 2CompletedAxalbion SA1082021-08-112025-09-08
Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN)
Hesperidin, Placebo - Covid19, Anosmia
Phase 2CompletedMontreal Heart Institute2162021-02-182022-04-08
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
BLU-5937, Placebo - Refractory Chronic Cough
Phase 2CompletedBellus Health Inc. - a GSK company3102020-12-072021-12-13
The Effects of Salbutamol on Mannitol Induced Cough Responses in Healthy Controls
Salbutamol 5mg/mL, Sodium Chloride 0.9% Inhl 3Ml - Cough
Phase 2CompletedMcMaster University202020-11-302022-06-16
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
BAY1817080, Placebo - Refractory and/or Unexplained Chronic Cough
Phase 2CompletedBayer3102020-10-022022-08-18
Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children
High dose Susu Xiao'er Zhike Granules 1 bag, Middle dose Susu Xiao'er Zhike Granules 1 bag, Extremely-low dose Susu Xiao'er Zhike Granules 1 bag - Cough
Phase 2CompletedTasly Pharmaceutical Group Co., Ltd2402020-09-192024-09-05
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
Ifenprodil - Idiopathic Pulmonary Fibrosis
Phase 2CompletedAlgernon Pharmaceuticals202020-07-292022-07-19
Evaluation of S-600918 in Adults With Refractory Chronic Cough
S-600918, Placebo to S-600918 - Chronic Cough
Phase 2CompletedShionogi4062020-02-132024-03-27
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
NAL ER, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2CompletedTrevi Therapeutics422019-10-292025-05-29
Influence on Cough and Airway Symptoms by Oral Capsaicin
Capsicum Oleoresin, Placebos - Cough
Phase 2CompletedVastra Gotaland Region552019-06-012026-09-01
A Dose Escalation Study of Bradanicline in Refractory Chronic Cough
Bradanicline, Placebo - Chronic Cough
Phase 2CompletedAttenua, Inc.462018-11-052019-06-20
Repeat Doses of BAY1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients
BAY1902607, Matching placebo, Midazolam - Cough
Phase 1 / Phase 2CompletedBayer592018-05-292021-02-10

Showing 20 of 48. Sign in to see all of them.

Narrower conditions

Chronic Cough (19)  ·  Idiopathic Pulmonary Fibrosis (5)  ·  Parkinson Disease (3)  ·  Deglutition Disorders (2)  ·  Abdominal Pain (1)  ·  Anosmia (1)  ·  Arthralgia (1)  ·  COVID-19 (1)  ·  Chest Pain (1)  ·  Common Cold (1)  ·  Confusion (1)  ·  Dyspnea (1)  ·  Fever (1)  ·  Headache (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (48)  ·  Respiration Disorders (48)  ·  Respiratory Tract Diseases (48)  ·  Signs and Symptoms (48)  ·  Signs and Symptoms, Respiratory (48)  ·  Lung Diseases (8)  ·  Nervous System Diseases (6)  ·  Central Nervous System Diseases (5)  ·  Lung Diseases, Interstitial (5)  ·  Pulmonary Fibrosis (5)  ·  Brain Diseases (4)  ·  Pathologic Processes (4)  ·  Basal Ganglia Diseases (3)  ·  Infections (3)

Interventions

Gefapixant (8)  ·  Capsaicin (4)  ·  Nalbuphine (3)  ·  8-(bis(2-chlorophenyl)methyl)-3-(2-pyrimidinyl)-8-azabicyclo(3.2.1)octan-3-ol (2)  ·  ADX-629 (1)  ·  Acetylcysteine (1)  ·  Albuterol (1)  ·  BLU-5937 (1)  ·  DNK 333 (1)  ·  Hesperidin (1)  ·  Lidocaine (1)  ·  Midazolam (1)  ·  Respiratory Physiological Phenomena (1)  ·  Sodium Chloride (1)  ·  Zinc Acetate (1)

Sponsors

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (7)  ·  Merck Sharp & Dohme LLC (4)  ·  University of Florida (4)  ·  Bayer (3)  ·  Trevi Therapeutics (3)  ·  Novartis (2)  ·  Aldeyra Therapeutics, Inc. (1)  ·  Algernon Pharmaceuticals (1)  ·  Attenua, Inc. (1)  ·  Axalbion SA (1)  ·  Bellus Health Inc. - a GSK company (1)  ·  Dexa Medica Group (1)  ·  GlaxoSmithKline (1)  ·  Guangdong Hengrui Pharmaceutical Co., Ltd (1)  ·  Hull University Teaching Hospitals NHS Trust (1)

Countries

United Kingdom (16)  ·  United States (15)  ·  Canada (7)  ·  Netherlands (6)  ·  Poland (4)  ·  Australia (3)  ·  China (3)  ·  Czechia (3)  ·  Germany (3)  ·  Japan (3)  ·  Hungary (2)  ·  Indonesia (2)  ·  Italy (2)  ·  Spain (2)  ·  Taiwan (2)

Top investigators

Alexandra E. Brandimore, M.A. (1)  ·  Alexandra E. Brandimore, M.A. CCC/SLP (1)  ·  Alyn H Morice (1)  ·  Ardi Zulfariansyah, MD (1)  ·  Christine M Sapienza, Ph.D. (1)  ·  Dewi S Rosdiana, Dr,MD,MKes (1)  ·  Eva Millqvist, MD, PhD (1)  ·  Gail Gauvreau, PhD (1)  ·  Ignatia K Hallis, MD (1)

Results publications

PMID 15966463, PMID 19029430, PMID 19937046, PMID 25467586, PMID 25811287, PMID 27130637, PMID 28923239, PMID 31023843, PMID 31949115, PMID 32109425, PMID 33825965, PMID 33986030, PMID 34152585, PMID 34697975, PMID 35614875, PMID 35624408, PMID 36345090, PMID 36348054, PMID 36512069, PMID 37041539, PMID 37261531, PMID 38044419, PMID 38320144, PMID 40043302, PMID 40498172, PMID 41569557, PMID 42548348

NIH funding

2015 (4), 2017 (2), 2018 (2), 2016 (1), 2019 (1), R34HL132369 (1)